Table 4.
Odds ratios and 26-week probabilities for safety outcomes, fixed effects mixed treatment comparison
| Treatment | OR | LCrI | UCrI | 26-week probability (%) | LCrI (%) | UCrI (%) | Treatment is best (%) |
|---|---|---|---|---|---|---|---|
| Clinically significant (>7%) weight gain | |||||||
| Placebo | 1 | 5.4 | 3.6 | 7.2 | 89.7 | ||
| Aripiprazole once-monthly | 2.24 | 1.22 | 3.96 | 11.2 | 6.5 | 18.4 | 0.3 |
| Haloperidol depot | – | – | – | – | – | ||
| Olanzapine pamoate | 2.42 | 1.25 | 4.48 | 12.0 | 6.6 | 20.3 | 0.3 |
| Paliperidone palmitate | 2.47 | 0.78 | 6.21 | 11.9 | 4.2 | 26.1 | 4.5 |
| Risperidone LAI | 2.70 | 0.77 | 7.22 | 12.8 | 4.2 | 29.1 | 4.9 |
| Aripiprazole oral | 2.45 | 1.25 | 4.48 | 12.1 | 6.6 | 20.3 | 0.4 |
| Olanzapine oral | 3.24 | 1.64 | 6.14 | 15.3 | 8.5 | 25.9 | 0 |
| EPS | |||||||
| Placebo | 1 | 9.1 | 6.8 | 11.5 | 37.9 | ||
| Aripiprazole once-monthly | 1.68 | 1.07 | 2.55 | 14.3 | 9.7 | 20.4 | 0.3 |
| Haloperidol depot | – | – | – | – | – | ||
| Olanzapine pamoate | 1.14 | 0.58 | 2.12 | 10.1 | 5.5 | 17.6 | 24.0 |
| Paliperidone palmitate | 1.99 | 0.89 | 3.94 | 16.3 | 8.2 | 28.4 | 2.5 |
| Risperidone LAI | 2.43 | 0.99 | 5.23 | 19.1 | 9.0 | 34.5 | 0.8 |
| Aripiprazole oral | 1.43 | 0.83 | 2.33 | 12.5 | 7.7 | 19.0 | 6.4 |
| Olanzapine oral | 1.14 | 0.54 | 2.24 | 10.2 | 5.1 | 18.4 | 28.1 |
OR=odds ratio; LCrI=95% lower credible interval; UCrI=95% upper credible interval.